Status:

TERMINATED

Phase IIB Pilot of Atazanavir + Raltegravir

Lead Sponsor:

Bristol-Myers Squibb

Collaborating Sponsors:

Merck Sharp & Dohme LLC

Conditions:

HIV

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this study is to determine if the combination of atazanavir and raltegravir taken together is safe and effective in the treatment of human immunodeficiency virus (HIV).

Eligibility Criteria

Inclusion

  • Human Immunodeficiency Virus (HIV)-1 positive status
  • HIV ribonucleic acid (RNA) level \>=5000 copies/mL
  • Antiretroviral treatment-naive
  • Absolute Cluster of Differentiation 4 (CD4) cell count meeting 1 of the following criteria:
  • \<350 cells/mm\^3
  • Screening CD4 \>=350 and \<=500 cells/mm\^3 ONLY if at least 1 of the following conditions apply:
  • Screening HIV RNA level \>100,000 copies/mL, or
  • CD4 decline \>50-100 cells/mm\^3/year, or
  • Age \>=55 years
  • Any CD4 cell count, if participant has a history of an acquired immune deficiency syndrome-defining illness
  • Medically stable

Exclusion

  • Screening HIV genotype showing resistance to any component of the study regimen (Atazanavir, Raltegravir, Tenofovir/Emtricitabine)
  • Hepatitis B or hepatitis C coinfection
  • History of or current cardiac disease
  • Electrocardiogram findings:
  • PR Interval \>260 msec (severe 1st degree atrioventricular block)
  • QRS Interval \>120 msec

Key Trial Info

Start Date :

November 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2010

Estimated Enrollment :

167 Patients enrolled

Trial Details

Trial ID

NCT00768989

Start Date

November 1 2008

End Date

May 1 2010

Last Update

February 24 2012

Active Locations (16)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (16 locations)

1

Southwest Center For HIV/AIDS

Phoenix, Arizona, United States, 85006

2

Yale University School Of Medicine

New Haven, Connecticut, United States, 06510

3

Dupont Circle Physicians Group

Washington D.C., District of Columbia, United States, 20009

4

Orlando Immunology Center

Orlando, Florida, United States, 32803